Show simple item record

dc.contributor.authorFaraone, Stephen V.
dc.contributor.authorZhang-James, Yanli
dc.date.accessioned2021-06-30T14:38:48Z
dc.date.available2021-06-30T14:38:48Z
dc.date.issued2013-10-17
dc.identifier.citationFaraone, SV, Zhang-James, Y. 2013. Can sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity disorder? An in silico approach. Am J Med Genet Part B 162B: 711– 717.en_US
dc.identifier.issn1552-4841
dc.identifier.doi10.1002/ajmg.b.32155
dc.identifier.urihttp://hdl.handle.net/20.500.12648/1793
dc.description.abstractMedications for attention deficit hyperactivity disorder (ADHD) are only partially effective. Ideally, new treatment targets would derive from a known pathophysiology. Such data are not available for ADHD. We combine evidence for new etiologic pathways with bioinformatics data to assess the possibility that existing drugs might be repositioning for treating ADHD. We use this approach to determine if prior data implicating the sodium/hydrogen exchanger 9 gene (SLC9A9) in ADHD implicate sodium/hydrogen exchange (NHE) inhibitors as potential treatments. We assessed the potential for repositioning by assessing the similarity of drug–protein binding profiles between NHE inhibitors and drugs known to treat ADHD using the Drug Repositioning and Adverse Reaction via Chemical–Protein Interactome server. NHE9 shows a high degree of amino acid similarity between NHE inhibitor sensitive NHEs in the region of the NHE inhibitor recognition site defined for NHE1. We found high correlations in drug–protein binding profiles among most ADHD drugs. The drug–protein binding profiles of some NHE inhibitors were highly correlated with ADHD drugs whereas the profiles for a control set of nonsteroidal anti-inflammatory drugs (NSAIDs) were not. Further experimental work should evaluate if NHE inhibitors are suitable for treating ADHD. © 2013 Wiley Periodicals, Inc.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://doi.wiley.com/10.1002/tdm_license_1.1
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectGenetics(clinical)en_US
dc.subjectCellular and Molecular Neuroscienceen_US
dc.subjectPsychiatry and Mental healthen_US
dc.subjectsodium/hydrogen exchange; SLC9A9; NHE9;ADHD; drug repositioning; sodium–hydrogen inhibitors; geneticsen_US
dc.titleCan sodium/hydrogen exchange inhibitors be repositioned for treating attention deficit hyperactivity disorder? An in silico approachen_US
dc.typeArticleen_US
dc.source.journaltitleAmerican Journal of Medical Genetics Part B: Neuropsychiatric Geneticsen_US
dc.source.volume162
dc.source.issue7
dc.source.beginpage711
dc.source.endpage717
dc.description.versionVoRen_US
refterms.dateFOA2014-10-18T00:00:00Z
dc.description.institutionUpstate Medical Universityen_US
dc.description.departmentPsychiatryen_US
dc.description.degreelevelN/Aen_US


This item appears in the following Collection(s)

Show simple item record